Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Patricia, Bukczynska"'
Autor:
Heidi Fettke, Chao Dai, Edmond M. Kwan, Tiantian Zheng, Pan Du, Nicole Ng, Patricia Bukczynska, Maria Docanto, Louise Kostos, Siavash Foroughi, Stephen Brown, Lisa-Jane K. Graham, Kate Mahon, Lisa G. Horvath, Shidong Jia, Manish Kohli, Arun A. Azad
Publikováno v:
EBioMedicine, Vol 95, Iss , Pp 104738- (2023)
Summary: Background: Genomic alterations in DNA damage response (DDR) genes are common in metastatic castration-resistant prostate cancer (mCRPC). Understanding how these genomic events impact prognosis and/or treatment response is vital for optimisi
Externí odkaz:
https://doaj.org/article/868bde2315c940f2aff0e43052a1b905
Autor:
Heidi Fettke, Jason A Steen, Edmond M Kwan, Patricia Bukczynska, Shivakumar Keerthikumar, David Goode, Maria Docanto, Nicole Ng, Luciano Martelotto, Christine Hauser, Melissa C Southey, Arun A Azad, Tu Nguyen-Dumont
Publikováno v:
BioTechniques, Vol 69, Iss 2, Pp 133-140 (2020)
Plasma circulating tumor DNA (ctDNA) analysis has emerged as a minimally invasive means to perform molecular tumor typing. Here we developed a custom ultra-sensitive ctDNA next-generation sequencing assay using molecular barcoding technology and off-
Externí odkaz:
https://doaj.org/article/426ccb7d425e4c5d9137c70096bb5e8a
Autor:
Zhixin Zhao, Edmond M. Kwan, Pan Du, Manish Kohli, Arun Azad, Heidi Fettke, Winston Tan, Tiantian Zheng, Jianjun Yu, Maria Docanto, Christine Hauser, Patricia Bukczynska, Kemin Zhou, Xiaohong Wang, Chao Dai, Shidong Jia, Lisa-Jane K Graham, Nicole Ng, Siavash Foroughi, Kate L. Mahon, Lisa G. Horvath
Publikováno v:
JCO Precis Oncol
PURPOSE Tumor tissue from metastatic castration-resistant prostate cancer (mCRPC) harbors frequent copy number variations (CNVs) in the PTEN-PI3K-AKT pathway. However, identifying CNVs in plasma cell–free DNA (cfDNA) has proven to be challenging. W
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88ee7982a95bf2ec733ddc8190b79ad7
https://doi.org/10.1200/po.20.00424
https://doi.org/10.1200/po.20.00424
Autor:
Maria Docanto, Christine Hauser, Edmond M. Kwan, Nicole Ng, Jason A. Steen, Siavash Foroughi, Melissa C. Southey, Arun Azad, Phillip Parente, Heidi Fettke, Carmel Pezaro, Patricia Bukczynska, Andrew Mant, Tu Nguyen-Dumont
Publikováno v:
The Prostate. 81:992-1001
Background The androgen receptor (AR) pathway-associated gene nuclear receptor coactivator 2 (NCOA2) has an established oncogenic role in early prostate cancer and likewise is a driver of metastatic disease and castration-resistant prostate cancer. H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acb05eac6614552e4b1dfc47ed114ed8
https://doi.org/10.1002/pros.24194
https://doi.org/10.1002/pros.24194
Autor:
Edmond M. Kwan, Kate L. Mahon, Tilman Todenhöfer, Phillip Parente, Sarah Azer, Patricia Bukczynska, Ian D. Davis, Lisi Elizabeth Lim, Niranjan J. Sathianathen, Lisa G. Horvath, Lisa-Jane K Graham, Maria Docanto, Nicole Ng, Heidi Fettke, Christine Hauser, Anne-Maree Haynes, Carmel Pezaro, Siavash Foroughi, Megan Crumbaker, Sarah Q. To, Arun Azad, Anthony M. Joshua, Andrew Mant, Eva Segelov
Publikováno v:
Translational Andrology and Urology. 10:1688-1699
Background: As potent systemic therapies transition earlier in the prostate cancer disease course, molecular biomarkers are needed to guide optimal treatment selection for metastatic hormone-sensitive prostate cancer (mHSPC). The value of whole blood
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::00b82b83eb05aafbdca2c1a33f20b3bf
https://doi.org/10.21037/tau-20-1444
https://doi.org/10.21037/tau-20-1444
Autor:
Heidi Fettke, Louise Kostos, James Buteau, Jason A. Steen, Elizabeth Medhurst, Mo B. Haskali, Declan Murphy, Maria Docanto, Patricia Bukczynska, Nicole Ng, Shahneen Sandhu, Siavash Foroughi, Luc Furic, Tu Nguyen-Dumont, Michael S. Hofman, Arun A. Azad
Publikováno v:
Cancer Research. 83:5614-5614
[177Lu]Lu-PSMA-617 (LuPSMA) radionuclide therapy improves overall survival in mCRPC, and was recently approved by the FDA. Nevertheless, owing to the heterogeneous nature of mCRPC, responses to LuPSMA therapy can be variable, and resistance is inevit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::129d7c0027982a36e572f1f49231a3b4
https://doi.org/10.1158/1538-7445.am2023-5614
https://doi.org/10.1158/1538-7445.am2023-5614
Autor:
Tilman Todenhöfer, Lisa G. Horvath, Andrew Mant, Maria Docanto, Edmond M. Kwan, Nicole Ng, Stefano Mangiola, Kate L. Mahon, Ian D. Davis, Sarah Q. To, David Pook, Lisa Jane K. Graham, Arun Azad, Heidi Fettke, Carmel Pezaro, Phillip Parente, Patricia Bukczynska, Eva Segelov
Publikováno v:
European Urology Focus. 7:63-70
The treatment paradigm for metastatic castration-resistant prostate cancer (mCRPC) has evolved significantly in recent years. Identifying predictive and/or prognostic biomarkers in the context of this rapidly expanding therapeutic armamentarium remai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cb31148479814a82d3266e533c52e3e
https://doi.org/10.1016/j.euf.2019.04.020
https://doi.org/10.1016/j.euf.2019.04.020
Autor:
James Patrick Buteau, Louise Kathleen Kostos, Ramin Alipour, Price Jackson, Lachlan McIntosh, Brittany Emmerson, Mohammad B Haskali, Theresa Yeung, Sophia Xie, Elizabeth Medhurst, Rajeev Ravi, Brian D. Gonzalez, Heidi Fettke, Nicole Ng, Maria Docanto, Patricia Bukczynska, Benjamin Blyth, Luc Furic, Arun Azad, Michael S Hofman
Publikováno v:
Journal of Clinical Oncology. 41:TPS281-TPS281
TPS281 Background: [177Lu]Lu-PSMA is an effective class of therapy for men with metastatic castration-resistant prostate cancer (mCRPC); however, progression is inevitable. The limited durability of response is partially explained by the presence of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c98f01a7d11553724c3c6c8b56e88af
https://doi.org/10.1200/jco.2023.41.6_suppl.tps281
https://doi.org/10.1200/jco.2023.41.6_suppl.tps281
Autor:
Edmond M, Kwan, Heidi, Fettke, Megan, Crumbaker, Maria M, Docanto, Sarah Q, To, Patricia, Bukczynska, Andrew, Mant, Nicole, Ng, Siavash, Foroughi, Lisa-Jane K, Graham, Anne-Maree, Haynes, Sarah, Azer, Lisi Elizabeth, Lim, Eva, Segelov, Kate, Mahon, Ian D, Davis, Phillip, Parente, Carmel, Pezaro, Tilman, Todenhöfer, Niranjan, Sathianathen, Christine, Hauser, Lisa G, Horvath, Anthony M, Joshua, Arun A, Azad
Publikováno v:
Transl Androl Urol
BACKGROUND: As potent systemic therapies transition earlier in the prostate cancer disease course, molecular biomarkers are needed to guide optimal treatment selection for metastatic hormone-sensitive prostate cancer (mHSPC). The value of whole blood
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4f0bace130d69e45160d4caad46e98cc
https://pubmed.ncbi.nlm.nih.gov/33968657
https://pubmed.ncbi.nlm.nih.gov/33968657
Autor:
Heidi Fettke, Nicole Ng, Christine Hauser, Patricia Bukczynska, Elizabeth Medhurst, Louise Kostos, James Buteau, Jason Steen, Tu Nguyen-Dumont, Michael Hofman, Arun A. Azad
Publikováno v:
Cancer Research. 82:532-532
Recent clinical trials have revealed that Lutetium PSMA-617 (Lu-PSMA, a small molecular inhibitor of prostate-specific membrane antigen radiolabelled with the beta emitter 177-Lutetium) significantly improves clinical outcomes including overall survi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::349d2c47055f7cbf499cfc52de72fcf1
https://doi.org/10.1158/1538-7445.am2022-532
https://doi.org/10.1158/1538-7445.am2022-532